Core Viewpoint - The company has decided to pursue a dual primary listing on the NASDAQ stock market through an initial public offering of American Depositary Shares, which is a significant step in its global strategic layout, expected to bring multiple positive impacts. Group 1: Global Financing and Market Expansion - The dual listing is anticipated to expand the company's global financing channels by entering one of the largest and most comprehensive capital markets, potentially attracting more long-term international investors focused on biotechnology and healthcare [1]. - This move is expected to provide strong capital support for the company's future research and commercialization efforts [1]. Group 2: Brand and Market Presence - Listing on NASDAQ will enhance the company's international brand influence, improving its corporate image and industry recognition in the global market [1]. - It will also increase opportunities for communication and collaboration with potential global partners, clients, and regulatory bodies [1]. Group 3: Share Liquidity and Valuation - The establishment of a cross-market trading mechanism is expected to broaden the investor base and enhance overall share liquidity [1]. - This environment will allow the company's long-term value to be fully reflected in a more international pricing context [1]. Group 4: Governance and Transparency - Adhering to U.S. securities regulations and disclosure requirements will improve the company's governance standards and operational transparency [1]. - This compliance is likely to strengthen the company's global compliance image and investor trust [1]. Group 5: Strategic Flexibility - The dual listing structure will provide the company with greater flexibility for future international collaborations, mergers, and business expansions, offering a richer platform for capital operations and strategic choices [2].
华检医疗就建议于美国双重上市保密提交F-1表格登记声明草案